CsA-based post-graft immunosuppression: The main factor for improving outcome of allografted patients with acquired aplastic anemia: A retrospective survey by the Spanish Group of Hematopoietic Transplantation

Bone Marrow Transplantation

Volumn 29, Issue 3, 2002, Pages 205-211

  Arranz, R ^a   Conde, E ^b   Rodriguez Salvanes F ^a   Pajuelo, F J ^a   Cabrera, R ^c   Sanz, M A ^d   Petit, J ^e   Bueno, J ^f   Maldonado, J ^g   Odriozola, J ^h   Conde, J G ⁱ   Brunet, S ^j   Carreras, E ^k   Iriondo, A ^b   Fernandez Ranada J M ^a   Marin P ^k  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j Sant Pau University Hospital   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

Acquired aplastic anemia; Bone marrow transplantation; Conditioning regimen; Post grafting immunosuppression; Survival

Indexed keywords

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, ISOGENEIC; TREATMENT OUTCOME;

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; PROCARBAZINE; THYMOCYTE ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SPAIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85047697191     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703349     Document Type: Article

References (30)

1. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anemia (SAA): A report of the EBMT SAA Working Party
2. Bone marrow transplantation for severe aplastic anemia: Influence of conditioning and graft versus host disease prophylaxis regimens on outcome
3. Bone marrow transplantation for severe aplastic anemia: Has outcome improved?
4. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for Blood and Marrow Transplantation experience
5. Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy
6. Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: Long term follow up
7. Improved survival following bone marrow transplantation for aplastic anemia
8. Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation
9. Bone marrow transplantation for severe aplastic anemia using cyclosporine: Long-term follow-up
10. Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia
11. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia
12. Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia
13. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
14. Long term follow-up of a randomised trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia
15. Cyclosporin A and short term methotrexate versus cyclosporine A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical GITMO/EBMT randomised trial
16. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia
17. Efficacy of cyclophosphamide-procarbazine-antithymocyte serum regimens for prevention of graft rejection following bone marrow transplantation for transfused patients with aplastic anemia
18. Total lymphoid irradiation and cyclophosphamide conditioning prior to bone marrow transplantation for patients with severe aplastic anemia
19. Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anaemia
20. Nonparametric estimation from incomplete estimations
21. Survival Analysis: A Practical Approach
22. Epidemiologic Research: Principles and Quantitative Methods
23. Long term outcome of aplastic anemia in adults treated with antithymocyte globulin: Comparison with bone marrow transplantation
24. Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results
25. Graft rejection and second bone marrow transplants for acquired aplastic anemia: A report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group
26. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical siblings bone marrow transplants for early leukemia?
27. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience of four centers
28. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients
29. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia